Introduced:
Apr 21, 2025
Policy Area:
Health
Congress.gov:
Bill Statistics
3
Actions
0
Cosponsors
0
Summaries
1
Subjects
1
Text Versions
Yes
Full Text
AI Summary
AI Summary
No AI Summary Available
Click the button above to generate an AI-powered summary of this bill using Claude.
The summary will analyze the bill's key provisions, impact, and implementation details.
Error generating summary
Latest Action
Apr 21, 2025
Referred to the House Committee on Energy and Commerce.
Actions (3)
Referred to the House Committee on Energy and Commerce.
Type: IntroReferral
| Source: House floor actions
| Code: H11100
Apr 21, 2025
Submitted in House
Type: IntroReferral
| Source: Library of Congress
| Code: H11100
Apr 21, 2025
Submitted in House
Type: IntroReferral
| Source: Library of Congress
| Code: 1025
Apr 21, 2025
Subjects (1)
Health
(Policy Area)
Full Bill Text
Length: 2,204 characters
Version: Introduced in House
Version Date: Apr 21, 2025
Last Updated: Nov 15, 2025 6:22 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 342 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. RES. 342
Recognizing the history of the drug diethylstilbestrol and the harm it
has caused, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
April 21, 2025
Mr. McGovern submitted the following resolution; which was referred to
the Committee on Energy and Commerce
_______________________________________________________________________
RESOLUTION
Recognizing the history of the drug diethylstilbestrol and the harm it
has caused, and for other purposes.
Whereas diethylstilbestrol (``DES'') is a toxic and carcinogenic estrogen and
endocrine disrupter;
Whereas the Food and Drug Administration (``FDA'') approved DES in the early
1940s;
Whereas DES was widely prescribed, with the intention of preventing miscarriage,
to between five and ten million pregnant women in the United States
until 1971;
Whereas DES exposure in utero was linked to the development of rare cancers of
the vagina and cervix called clear cell adenocarcinoma in female
children, commonly referred to as ``DES Daughters'';
Whereas the FDA banned the use of DES during pregnancy in the United States in
1971;
Whereas DES exposure in utero has since been linked to increased fertility and
pregnancy complications and other physical and mental health challenges;
Whereas the FDA has acknowledged the harm caused by DES but has yet to apologize
to the families of those impacted by its prolonged use; and
Whereas April 20 through 26, 2025, would be an appropriate week to designate as
``DES Awareness Week'': Now, therefore, be it
Resolved, That the House of Representatives--
(1) expresses support for the designation of ``DES
Awareness Week'';
(2) recognizes the history of the drug diethylstilbestrol
and the harm it has caused;
(3) supports the restoration of funding for the DES Follow-
Up Study; and
(4) urges the Food and Drug Administration to issue a
formal apology to families impacted by diethylstilbestrol.
<all>
[From the U.S. Government Publishing Office]
[H. Res. 342 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. RES. 342
Recognizing the history of the drug diethylstilbestrol and the harm it
has caused, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
April 21, 2025
Mr. McGovern submitted the following resolution; which was referred to
the Committee on Energy and Commerce
_______________________________________________________________________
RESOLUTION
Recognizing the history of the drug diethylstilbestrol and the harm it
has caused, and for other purposes.
Whereas diethylstilbestrol (``DES'') is a toxic and carcinogenic estrogen and
endocrine disrupter;
Whereas the Food and Drug Administration (``FDA'') approved DES in the early
1940s;
Whereas DES was widely prescribed, with the intention of preventing miscarriage,
to between five and ten million pregnant women in the United States
until 1971;
Whereas DES exposure in utero was linked to the development of rare cancers of
the vagina and cervix called clear cell adenocarcinoma in female
children, commonly referred to as ``DES Daughters'';
Whereas the FDA banned the use of DES during pregnancy in the United States in
1971;
Whereas DES exposure in utero has since been linked to increased fertility and
pregnancy complications and other physical and mental health challenges;
Whereas the FDA has acknowledged the harm caused by DES but has yet to apologize
to the families of those impacted by its prolonged use; and
Whereas April 20 through 26, 2025, would be an appropriate week to designate as
``DES Awareness Week'': Now, therefore, be it
Resolved, That the House of Representatives--
(1) expresses support for the designation of ``DES
Awareness Week'';
(2) recognizes the history of the drug diethylstilbestrol
and the harm it has caused;
(3) supports the restoration of funding for the DES Follow-
Up Study; and
(4) urges the Food and Drug Administration to issue a
formal apology to families impacted by diethylstilbestrol.
<all>